TTrialPathMatch Me to Trials
← Back to trials
RecruitingMajor Depressive Disorder

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Eligible age

18+ yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The study will evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Sponsor: Neurocrine Biosciences

Where it's recruiting

California

Chino · Los Angeles · Stanford

Colorado

Aurora

Connecticut

Cromwell · Farmington

Florida

Maitland · Miami · Tampa

Illinois

Skokie

Maryland

Gaithersburg

Nevada

Las Vegas

New Jersey

Cherry Hill

New York

Cedarhurst · New York

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT06963021 · last updated 2026-11-19

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavam · TrialPath